



NDA 21-077/S-047  
NDA 21-254/S-016  
NDA 20-692/S-039

**SUPPLEMENT APPROVAL  
REMOVE REMS ELEMENT**

GlaxoSmithKline  
P. O. Box 13398  
Five Moore Drive  
Research Triangle Park, NC 27709-3398

Attention: Kevin C. Fitzgerald, R.Ph.  
Director, Regulatory Affairs

Dear Mr. Fitzgerald:

Please refer to your Supplemental New Drug Applications (sNDAs) dated May 3, 2011, received May 3, 2011, submitted under section 505(b)/pursuant to section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Advair Diskus (fluticasone propionate and salmeterol xinafoate inhalation powder), Advair HFA (fluticasone propionate and salmeterol xinafoate) Inhalation Aerosol, and Serevent Diskus (salmeterol xinafoate inhalation powder).

We acknowledge receipt of your amendments dated May 24, 2011, and your risk evaluation and mitigation strategy (REMS) assessments, dated June 23, 2011.

These Prior Approval supplemental new drug applications propose to eliminate the Medication Guide as an element of the approved Advair Diskus (fluticasone propionate and salmeterol xinafoate inhalation powder), Advair HFA (fluticasone propionate and salmeterol xinafoate) Inhalation Aerosol, and Serevent Diskus (salmeterol xinafoate inhalation powder) REMS.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter.

**RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS**

The REMS for Advair Diskus (fluticasone propionate and salmeterol xinafoate inhalation powder) was originally approved on April 30, 2008. The REMS for Advair HFA (fluticasone propionate and salmeterol xinafoate) Inhalation Aerosol was originally approved on July 31, 2008. The REMS for Serevent Diskus (salmeterol xinafoate inhalation powder) was originally approved on November 18, 2010. The most recent REMS modification for all three products was approved on May 10, 2011. The REMS consists of a Medication Guide, communication plan, and a timetable for submission of assessments of the REMS.

NDA 21-077/S-047

NDA 21-254/S-016

NDA 20-692/S-039

Page 2

Your proposed modifications to these REMS consist of eliminating the requirement for the Medication Guide as an element of the REMS.

We have determined that maintaining the Medication Guide as part of the approved labeling is adequate to address the serious and significant public health concern and meets the standard in 21 CFR 208.1.

Therefore, it is no longer necessary to include the Medication Guide as an element of the approved REMS to ensure that the benefits of Advair Diskus (fluticasone propionate and salmeterol xinafoate inhalation powder), Advair HFA (fluticasone propionate and salmeterol xinafoate) Inhalation Aerosol, and Serevent Diskus (salmeterol xinafoate inhalation powder) outweigh the risks.

Therefore, we agree with your proposal, and a Medication Guide is/are no longer required as part of the REMS for Advair Diskus (fluticasone propionate and salmeterol xinafoate inhalation powder), Advair HFA (fluticasone propionate and salmeterol xinafoate) Inhalation Aerosol, and Serevent Diskus (salmeterol xinafoate inhalation powder).

Your proposed modified REMS, submitted on May 24, 2011, and appended to this letter, are approved.

The modified REMS consist of a communication plan and a timetable for submission of assessments of the REMS.

We remind you that the Medication Guide will continue to be part of the approved labeling for Advair Diskus (fluticasone propionate and salmeterol xinafoate inhalation powder), Advair HFA, (fluticasone propionate and salmeterol xinafoate) Inhalation Aerosol and Serevent Diskus (salmeterol xinafoate inhalation powder) in accordance with 21 CFR 208.

The timetable for submission of assessments of the REMS will remain the same as that approved on May 10, 2011.

There are no changes to the REMS assessment plan described in our November 18, 2010, letter for Serevent Diskus, and January 4, 2011, letter for Advair Diskus and Advair HFA.

We remind you that in addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of FDCA.

If you currently distribute or plan to distribute an authorized generic product under this NDA, you must submit a complete proposed REMS that relates only to the authorized generic product. Submit a proposed REMS, REMS supporting document, and any required appended documents

NDA 21-077/S-047

NDA 21-254/S-016

NDA 20-692/S-039

Page 3

as a prior approval supplement. Approval of the proposed REMS is required before you may market your authorized generic product.

Prominently identify the submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**NDA 21-077 REMS ASSESSMENT  
NDA 21-254 REMS ASSESSMENT  
NDA 20-692 REMS ASSESSMENT**

**NEW SUPPLEMENT FOR NDA 21-077  
NEW SUPPLEMENT FOR NDA 21-254  
NEW SUPPLEMENT FOR NDA 20-692  
PROPOSED REMS MODIFICATION  
REMS ASSESSMENT**

**NEW SUPPLEMENT (NEW INDICATION FOR USE)  
FOR NDA 21-077  
FOR NDA 21-254  
FOR NDA 20-692  
REMS ASSESSMENT  
PROPOSED REMS MODIFICATION (if included)**

If you do not submit electronically, please send 5 copies of REMS-related submissions.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Ladan Jafari, Safety Regulatory Project Manager, at (301) 796-1231.

Sincerely,

*{See appended electronic signature page}*

Sally Seymour, M.D.  
Deputy Director for Safety  
Division of Pulmonary, Allergy, and Rheumatology  
Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

NDA 21-077/S-047

NDA 21-254/S-016

NDA 20-692/S-039

Page 4

ENCLOSURE(S):

REMS

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SALLY M SEYMOUR  
06/27/2011